Denosumab

mAbs

Volumn 1, Issue 3, 2009, Pages 210-215

  Pageau, Steven C ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Bone loss; Breast cancer; Monoclonal antibody; Osteoporosis; RANKL; Rheumatoid arthritis

Indexed keywords

ALENDRONIC ACID; ALKALINE PHOSPHATASE; AMINO TERMINAL TELOPEPTIDE; BISPHOSPHONIC ACID DERIVATIVE; CREATININE; DENOSUMAB; METHOTREXATE; PLACEBO;

ABSENCE OF SIDE EFFECTS; BONE DENSITY; BONE DESTRUCTION; BONE METASTASIS; BONE TURNOVER; CANCER CHEMOTHERAPY; CHEMOPROPHYLAXIS; CLINICAL TRIAL; CREATININE BLOOD LEVEL; DOSE RESPONSE; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMUR NECK; FOOD AND DRUG ADMINISTRATION; GREATER TROCHANTER; HIP; HUMAN; LONG TERM CARE; LOW DRUG DOSE; LUMBAR SPINE; OSTEOLYSIS; PATIENT COMPLIANCE; POSTMENOPAUSE OSTEOPOROSIS; RADIUS; RETREATMENT; RHEUMATOID ARTHRITIS; SHORT COURSE THERAPY; SHORT SURVEY; SINGLE DRUG DOSE;

ANIMALS; ANTIBODIES, MONOCLONAL; ARTHRITIS, RHEUMATOID; BONE NEOPLASMS; BONE RESORPTION; BREAST NEOPLASMS; CLINICAL TRIALS AS TOPIC; DRUG APPROVAL; FEMALE; HUMANS; OSTEOPOROSIS, POSTMENOPAUSAL; RANK LIGAND; UNITED STATES;

EID: 77953672623     PISSN: 19420862     EISSN: None     Source Type: Journal    
DOI: 10.4161/mabs.1.3.8592     Document Type: Short Survey

References (18)

1. Matsuzaki K, Udagawa N, Takahashi N, Yamaguchi K, Yasuda H, Shima N, et al. Osteoclast differentiation factor (ODF) induces osteoclast-like cell formation in human peripheral blood mononuclear cell cultures. Biochem Biophys Res Commun 1998; 246:199-204. (Pubitemid 28413951)
2. Nakagawa N, Kinosaki M, Yamaguchi K, Shima N, Yasuda H, Yano K, et al. RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis. Biochem Biophys Res Commun 1998; 253:395-400. (Pubitemid 29026714)
3. Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S, et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/ osteoclastogenesisinhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 1998; 95:3597-3602 (Pubitemid 28173173)
4. Gerstenfeld LC, Sacks DJ, Pelis M, Mason ZD, Graves DT, Barrero M, et al. Comparison of Effects of the Bisphosphonate Alendronate Versus the RANKL Inhibitor Denosumab on Murine Fracture Healing. J Bone Miner Res 2009; 24:196-208.
5. Kostenuik P, Nguyen H, McCabe J, Warmington K, Kurahara C, Sun N, et al. Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases bone density in knock-in mice that express chimeric (murine/human) RANKL*. J Bone Miner Res 2009; 24:182-195
6. Bekker PJ, Holloway DL, Rasmussen AS, Murphy R, Martin SW, Leese PT, et al. A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. 2004. J Bone Miner Res 2005; 20:2275-2282 (Pubitemid 41110556)
7. Lewiecki EM, Miller PD, McClung MR, Cohen SB, Bolognese MA, Liu Y, et al. Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low BMD. J Bone Miner Res 2007; 22:1832-1841.
8. Miller PD, Bolognese MA, Lewiecki EM, McClung MR, Ding B, Austin M, et al. Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial. Bone 2008; 43:222-229
9. Brown JP, Prince RL, Deal C, Recker RR, Kiel DP, de Gregorio LH, et al. Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial. J Bone Miner Res 2009; 24:153-161
10. Mundy GR. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2002; 2:584-593 (Pubitemid 37328925)
11. Brown JE, Cook RJ, Major P, Lipton A, Saad F, Smith M, et al. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst 2005; 97:59-69.
12. Brown JE, Thomson CS, Ellis SP, Gutcher SA, Purohit OP, Coleman RE. Bone resorption predicts for skeletal complications in metastatic bone disease. Br J Cancer 2003; 89:2031-2037 (Pubitemid 38030899)
13. Costa L, Demers LM, Gouveia-Oliveira A, Schaller J, Costa EB, de Moura MC, et al. Prospective evaluation of the peptide-bound collagen type I cross-links N-telopeptide and C-telopeptide in predicting bone metastases status. J Clin Oncol 2002; 20:850-856 (Pubitemid 34111395)
14. Hortobagyi GN, Theriault RL, Lipton A, Porter L, Blayney D, Sinoff C, et al. Longterm prevention of skeletal complications of metastatic breast cancer with pamidronate. J Clin Oncol 1998; 16:2038-2044 (Pubitemid 28265038)
15. Wardley A, Davidson N, Barrett-Lee P, Hong A, Mansi J, Dodwell D, et al. Zoledronic acid significantly improves pain scores and quality of life in breast cancer patients with bone metastases: a randomised, crossover study of community vs hospital bisphosphonate administration. Br J Cancer 2005; 92:1869-1876 (Pubitemid 40826135)
16. Lipton A, Steger GG, Figueroa J, Alvarado C, Solal-Celigny P, Body JJ, et al. Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases. J Clin Oncol 2007; 25:4431-4437 (Pubitemid 350013849)
17. Fizazi K, Lipton A, Mariette X, Body JJ, Rahim Y, Gralow JR, et al. Randomized phase II rial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. J Clin Oncol, 2009; 27:1534-1536
18. Cohen SB, Dore RK, Lane NE, Ory PA, Peterfy CG, Sharp JT, et al. Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: a twelve-month, multicenter, randomized, double-blind, placebocontrolled, phase II clinical trial. Arthritis Rheum 2008; 58:1299-1309 (Pubitemid 351705919)